Trials / Unknown
UnknownNCT04309136
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 14 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment |
| PROCEDURE | surgery | Perform surgery if operable after neoadjuvant therapy |
| PROCEDURE | core needle biopsy | Perform core needle biopsy if inoperable after neoadjuvant therapy |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2021-02-01
- Completion
- 2022-06-01
- First posted
- 2020-03-16
- Last updated
- 2021-04-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04309136. Inclusion in this directory is not an endorsement.